AR and neoplasm: For example, the FDA‐approved Olaparib, an inhibitor of pan‐Poly(ADP‐ribose) Polymerase (PARP) in the DDR pathway, has been clinically used for treating Breast Cancer Gene 1/2 (BRCA1/2)‐deficient PCa [12], making research significant on AR downstream signaling, particularly in the DDR pathway.